<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T0001" orientation="portrait" position="float">
 <label>TABLE 1</label>
 <caption>
  <p>South African guidelines for treatment of adults with human immunodeficiency virus infection.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead valign="top">
   <tr>
    <th align="left" rowspan="1" colspan="1">Variable</th>
    <th align="left" rowspan="1" colspan="1">2004 guidelines</th>
    <th align="left" rowspan="1" colspan="1">April 2010 guidelines</th>
    <th align="left" rowspan="1" colspan="1">March 2013 guidelines
     <xref ref-type="table-fn" rid="TFN0001">†</xref>
    </th>
    <th align="left" rowspan="1" colspan="1">December 2014 guidelines
     <xref ref-type="table-fn" rid="TFN0002">‡</xref>
    </th>
    <th align="left" rowspan="1" colspan="1">August 2016 circular
     <xref ref-type="table-fn" rid="TFN0003">‡</xref>
    </th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td align="left" rowspan="1" colspan="1">ART eligibility</td>
    <td align="left" rowspan="1" colspan="1">CD4 count &lt; 200 cells/mm
     <sup>3</sup>
     <break/>
     <italic>or</italic>
     <break/>WHO Stage IV disease
    </td>
    <td align="left" rowspan="1" colspan="1">CD4 count ≤ 200 cells/mm
     <sup>3</sup>
     <break/>
     <italic>or</italic>
     <break/>CD4 count ≤ 350 cells/mm
     <sup>3</sup> in clients with TB/HIV or pregnant women
     <break/>
     <italic>or</italic>
     <break/>WHO stage IV disease
     <break/>
     <italic>or</italic>
     <break/>
     <break/>MDR/XDR-TB
    </td>
    <td align="left" rowspan="1" colspan="1">CD4 count ≤350 cells/mm
     <sup>3</sup>
     <xref ref-type="table-fn" rid="TFN0004">¶</xref>
     <break/>
     <italic>or</italic>
     <break/>WHO stage III or IV disease
     <break/>
     <italic>or</italic>
     <break/>Clients with all types of TB
    </td>
    <td align="left" rowspan="1" colspan="1">CD4 count ≤ 500 cells/mm
     <sup>3</sup>
     <break/>
     <italic>or</italic>
     <break/>WHO stage III or IV disease
     <break/>
     <italic>or</italic>
     <break/>Active TB disease
     <break/>
     <italic>or</italic>
     <break/>Pregnant and breastfeeding women
     <break/>
     <italic>or</italic>
     <break/>Known HBV co-infection
    </td>
    <td align="left" rowspan="1" colspan="1">UTT: all HIV-infected clients regardless of CD4 count</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">First-line ART regimen (new clients)</td>
    <td align="left" rowspan="1" colspan="1">d4T + 3TC + EFV/NVP</td>
    <td align="left" rowspan="1" colspan="1">TDF + 3TC/FTC + EFV/NVP</td>
    <td align="left" rowspan="1" colspan="1">FDC
     <xref ref-type="table-fn" rid="TFN0005">††</xref>
    </td>
    <td align="left" rowspan="1" colspan="1">FDC
     <xref ref-type="table-fn" rid="TFN0005">††</xref>
    </td>
    <td align="left" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">CPT</td>
    <td align="left" rowspan="1" colspan="1">All clients initiating ART</td>
    <td align="left" rowspan="1" colspan="1">CD4 ≤ 200 cells/mm
     <sup>3</sup>
     <break/>WHO stage II, III or IV disease (including TB)
    </td>
    <td align="left" rowspan="1" colspan="1"/>
    <td align="left" rowspan="1" colspan="1">CD4 count ≤ 200 cells/mm
     <sup>3</sup> WHO stage III or IV disease
     <break/>HIV/TB co-infection
    </td>
    <td align="left" rowspan="1" colspan="1"/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <italic>Source:</italic> National Department of Health of South Africa
    <sup>
     <xref rid="CIT0005" ref-type="bibr">5</xref>,
     <xref rid="CIT0006" ref-type="bibr">6</xref>,
     <xref rid="CIT0007" ref-type="bibr">7</xref>,
     <xref rid="CIT0008" ref-type="bibr">8</xref>,
     <xref rid="CIT0009" ref-type="bibr">9</xref>
    </sup>
   </p>
  </fn>
  <fn>
   <p>3TC, lamivudine; ART, antiretroviral therapy; CPT, cotrimoxazole preventive therapy; d4T, stavudine; EFV, efavirenz; FDC, fixed-dose combination; FTC, emtricitabine; HIV, human immunodeficiency virus; HBV, hepatitis B; MDR/XDR-TB, multidrug-resistant or extensively drug-resistant tuberculosis; NVP, nevirapine; TB, tuberculosis; TDF, tenofovir disoproxil fumarate; UTT, universal test and treat; WHO, World Health Organization</p>
  </fn>
  <fn id="TFN0001">
   <label>†</label>
   <p>, Implementation date = 01 April 2013;</p>
  </fn>
  <fn id="TFN0002">
   <label>‡</label>
   <p>,Implementation date = 01 January 2015;</p>
  </fn>
  <fn id="TFN0003">
   <label>‡</label>
   <p>, Implementation date = 01 September 2016;</p>
  </fn>
  <fn id="TFN0004">
   <label>¶</label>
   <p>, Implementation of the CD4 count ≤350 cell/mm
    <sup>3</sup> cut-off occurred in August 2011, prior to the publication of the 2013 guidelines
    <sup>
     <xref rid="CIT0010" ref-type="bibr">10</xref>
    </sup>;
   </p>
  </fn>
  <fn id="TFN0005">
   <label>††</label>
   <p>, FDC consists of TDF, FTC and EFV.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
